In addition, researchers have developed a new SLAMF 7 CAR-T product, which specifically targets SLAMF7 in both in vitro and mouse models by knocking out the SLAMF7 gene from T cells prior to the introduction of SLAMF7 CAR, effectively killing MM cell lines and primary human myeloma cells [58]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.